|
REPS1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.04409999979183E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.63620000051645E-07 |
| Normal-vs-Stage2 |
6.02880000000194E-05 |
| Normal-vs-Stage3 |
1.5909699999983E-05 |
| Normal-vs-Stage4 |
6.842500E-04 |
| Stage1-vs-Stage2 |
4.013200E-01 |
| Stage1-vs-Stage3 |
8.670200E-01 |
| Stage1-vs-Stage4 |
4.814000E-01 |
| Stage2-vs-Stage3 |
5.430200E-01 |
| Stage2-vs-Stage4 |
2.168400E-01 |
| Stage3-vs-Stage4 |
4.259600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.56200000045459E-07 |
| Normal-vs-AfricanAmerican |
6.021800E-01 |
| Normal-vs-Asian |
9.591600E-04 |
| Caucasian-vs-AfricanAmerican |
1.203870E-02 |
| Caucasian-vs-Asian |
4.827400E-01 |
| AfricanAmerican-vs-Asian |
8.266200E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.93230000017964E-07 |
| Normal-vs-Female |
2.69119999951606E-07 |
| Male-vs-Female |
6.746000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.00269999999225E-05 |
| Normal-vs-Age(41-60Yrs) |
9.00329999997673E-07 |
| Normal-vs-Age(61-80Yrs) |
1.52150999999101E-05 |
| Normal-vs-Age(81-100Yrs) |
4.795100E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.767000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.814400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.749640E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.737400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.521200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.713200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.576000E-01 |
| Classical-VS-Follicular |
1.823740E-04 |
| Classical-VS-Other |
2.070400E-01 |
| Classical-VS-Normal |
5.036600E-04 |
| Tall-VS-Follicular |
1.252970E-01 |
| Tall-VS-Other |
4.204200E-01 |
| Tall-VS-Normal |
6.848000E-04 |
| Follicular-VS-Other |
8.741800E-01 |
| Follicular-VS-Normal |
5.90780002696079E-09 |
| Other-VS-Normal |
4.438700E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.78089997882847E-09 |
| Normal-vs-N1 |
1.51079999999304E-06 |
| N0-vs-N1 |
6.994000E-01 |
|
|
